ArticleMolecules (Basel, Switzerland)2020
Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features.
Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of pregnant women with COVID-19 and their neonates.Archives of gynecology and obstetrics · 2021Pooled it
- Immuno-epigenetic paradigms in coronavirus infection.Frontiers in immunology · 2025Review
- SARS-CoV-2 Affects Both Humans and Animals: What Is the Potential Transmission Risk? A Literature Review.Microorganisms · 2023Review
- Co-infection associated with SARS-CoV-2 and their management.Future science OA · 2022Review
- A Study on the Nature of SARS-CoV-2 Using the Shell Disorder Models: Reproducibility, Evolution, Spread, and Attenuation.Biomolecules · 2022Article
- An Update of Lectins from Marine Organisms: Characterization, Extraction Methodology, and Potential Biofunctional Applications.Marine drugs · 2022Review
- A comprehensive account of SARS-CoV-2 genome structure, incurred mutations, lineages and COVID-19 vaccination program.Future virology · 2022Review
- Article
- Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.Drug development research · 2021Article
- Implications derived from S-protein variants of SARS-CoV-2 from six continents.International journal of biological macromolecules · 2021Article
- Non-Woven Infection Prevention Fabrics Coated with Biobased Cranberry Extracts Inactivate Enveloped Viruses Such as SARS-CoV-2 and Multidrug-Resistant Bacteria.International journal of molecular sciences · 2021Article
- 3D Printed Cobalt-Chromium-Molybdenum Porous Superalloy with Superior Antiviral Activity.International journal of molecular sciences · 2021Article
- GB-2 blocking the interaction between ACE2 and wild type and mutation of spike protein of SARS-CoV-2.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Article
- Article
- Epigenetic Mechanisms Underlying COVID-19 Pathogenesis.Biomedicines · 2021Review
- Review
- Altered immunoemotional regulatory system in COVID-19: From the origins to opportunities.Journal of neuroimmunology · 2021Review
- Animal Transmission of SARS-CoV-2 and the Welfare of Animals during the COVID-19 Pandemic.Animals : an open access journal from MDPI · 2021Review
- Special Issue-The Conformational Universe of Proteins and Peptides: Tales of Order and Disorder.Molecules (Basel, Switzerland) · 2021Article
- Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.Biomedicines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that is engendering the severe coronavirus disease 2019 (COVID-19) pandemic. The spike (S) protein receptor-binding domain (RBD) of SARS-CoV-2 binds to the three sub-domains viz. amino acids (aa) 22-42, aa 79-84, and aa 330-393 of ACE2 on human cells to initiate entry. It was reported earlier that the receptor utilization capacity of ACE2 proteins from different species, such as cats, chimpanzees, dogs, and cattle, are different. A comprehensive analysis of ACE2 receptors of nineteen species was carried out in this study, and the findings propose a possible SARS-CoV-2 transmission flow across these nineteen species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.